Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

CANAGLIFLOZIN vs CANAKINUMAB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

CANAGLIFLOZIN vs CANAKINUMAB: Safety Overview

Metric CANAGLIFLOZIN CANAKINUMAB
Total FAERS Reports 24,411 10,462
Deaths Reported 544 518
Death Rate 2.2% 5.0%
Hospitalizations 9,503 2,624
Average Patient Age 57.8 yrs 28.8 yrs
% Female Patients 49.1% 55.8%
FDA Approval Date Mar 29, 2013 N/A
Manufacturer Cardinal Health 107, LLC Novartis Pharmaceuticals Corporation
Route ORAL SUBCUTANEOUS
Marketing Status Prescription Prescription